Skip to content

Released Nov 7, 2025, before the open

10-Q filed Nov 7, 2025, 38 days after period end · 0001628280-25-050422

Q3 2025 · 10-Q
Revenue$1.23M+486.1% vs Q3 2024+9.9% vs Q2 2025
Net Income-$50.58MN/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.32N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$53,973,000N/M
Operating Cash Flowderived-$35,039,000N/M
Free Cash Flowderived-$35,286,000N/M
Margins · derived
Operating margin-4406.0%+21542.4 pt vs Q3 2024
Net margin-4129.1%+20999.1 pt vs Q3 2024

What the release said

The release

Same quarter

MetricQ3 2025Q3 2024Q3 2023Q3 2022
Revenue$1.23M$209.00K$0.00—
Net Income-$50.58M-$52.52M-$50.71M-$29.35M
EPS Diluted-$0.32-$0.44-$0.55-$1.61

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR